Green Thumb Industries (GTBIF) Cash & Equivalents (2018 - 2026)
Green Thumb Industries' (GTBIF) quarterly Cash & Equivalents came in at $344.5 million in Q1 2026, up 63.6% YoY from $210.6 million in Q1 2025, and up 25.6% on a QoQ basis from $274.3 million in Q4 2025.
Green Thumb Industries (GTBIF) Cash & Equivalents (2018 - 2026) Analysis & Trends
Green Thumb Industries (GTBIF) has 9 years of Cash & Equivalents data on file, last reported at $344.5 million in Q1 2026.
- Quarterly Cash & Equivalents rose 63.6% year-over-year to $344.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $344.5 million (up 63.6% YoY) and the FY2025 annual result came in at $274.3 million, up 59.77% from the prior year.
- Cash & Equivalents grew to $344.5 million in Q1 2026, from $274.3 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $344.5 million in Q1 2026 to a low of $136.8 million in Q3 2023.
- A 5-year average of $192.7 million and a median of $176.9 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents plunged 59.55% — and 2026, when it surged 63.6%.
- Tracing GTBIF's Cash & Equivalents over 5 years: stood at $177.7 million in 2022, then decreased by 9.03% to $161.6 million in 2023, then gained by 6.22% to $171.7 million in 2024, then jumped by 59.77% to $274.3 million in 2025, then advanced by 25.6% to $344.5 million in 2026.
- The last three Cash & Equivalents figures came in at $344.5 million (Q1 2026), $274.3 million (Q4 2025), and $226.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Green Thumb Industries | 1.65 Bn | 1.37 Bn | 137.87 Mn | 283.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 283.59 Mn |
| Mar 31, 2026 | 344.51 Mn |
| Dec 31, 2025 | 274.30 Mn |
| Sep 30, 2025 | 226.21 Mn |
| Jun 30, 2025 | 176.92 Mn |
| Mar 31, 2025 | 210.58 Mn |
| Dec 31, 2024 | 171.69 Mn |
| Sep 30, 2024 | 173.64 Mn |
| Jun 30, 2024 | 196.14 Mn |
| Mar 31, 2024 | 223.94 Mn |
| Dec 31, 2023 | 161.63 Mn |
| Sep 30, 2023 | 136.84 Mn |
| Jun 30, 2023 | 149.03 Mn |
| Mar 31, 2023 | 185.37 Mn |
| Dec 31, 2022 | 177.68 Mn |
| Sep 30, 2022 | 147.26 Mn |
| Jun 30, 2022 | 145.28 Mn |
| Mar 31, 2022 | 174.54 Mn |
| Dec 31, 2021 | 230.42 Mn |
| Sep 30, 2021 | 285.79 Mn |